Therapie zerebraler arteriovenöser Malformationen nach ARUBA – Kontra

Literatur
1 Dyken ML, White PT. Evaluation of cortisone in the treatment of cerebral infarction. JAMA 1956; 162: 1531-1534
2 Mohr JP, Parides MK, Stapf C et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (aruba): A multicentre, non-blinded, randomised trial. Lancet 2014; 383: 614-621
3 Mathiesen T. Arguments against the proposed randomized trial (aruba). Neuroradiology 2008; 50: 469-471
4 Cockroft K, Jayaraman M, Amin-Hanjani S et al. A perfect storm. How a randomized trial of unruptured brain arteriovenous malformations’ (aruba’s) trial design challenges notions of external validity. Stroke: a journal of cerebral circulation 2012; 43: 1979-1981
5 Stapf C, Mast H, Sciacca RR et al. Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology 2006; 66: 1350-1355
6 Wedderburn CJ, van Beijnum J, Bhattacharya JJ et al. Outcome after interventional or conservative management of unruptured brain arteriovenous malformations: A prospective, population-based cohort study. Lancet neurology 2008; 7: 223-230
7 Al-Shahi Salman R, White PM, Counsell CE et al. Outcome after conservative management or intervention for unruptured brain arteriovenous malformations. JAMA 2014; 311: 1661-1669
8 Josephson C, Bhattacharya J, Counsell C et al. Scottish audit of intracranial vascular malformations (saivms) steering committee and collaborators. Seizure risk with avm treatment or conservative management: Prospective, population-based study. Neurology 2012; 79: 500-507
9 Kim H, Al-Shahi Salman R, McCulloch CE et al. Untreated brain arteriovenous malformation: Patient-level meta-analysis of hemorrhage predictors. Neurology 2014; 83: 590-597
10 Stapf C, Parides MK, Moskowitz AJ et al. Management of brain arteriovenous malformations – authors’ reply. Lancet 2014; 383: 1635-1636